The spotting schema of the barcode sequences is the same of Fig 2A. (A) Cy3 fluorescence image and the plot of the relative fluorescence intensity of the sample identified with KRAS G12S mutation. (B) Cy3 fluorescence image and the plot of the relative fluorescence intensity of the sample identified with KRAS Q61H1 (c.183A>C) mutation. (C) Cy3 fluorescence image and the plot of the relative fluorescence intensity of the sample identified with NRAS G12V mutation. The yellow squares in the images were used to highlight more easily the analyzed spots. The bars are the average of the intensity of the 4 spots (2 X 2 subarray) of each barcode probe subarrays. The error bars are the standard deviations of the fluorescence intensity of each sample....
<p>Sequencing chromatographs are shown for the products from the real-time traditional PCR (top row)...
identifying actionable mutations in tumors. Accurate detection of mutations is often problematic in ...
Abstract Advanced cancer genomics technologies are now being employed in clinical sequencing, where ...
<p>(A) Cy5 fluorescence signal corresponding to the mutated allele. (B) spotting scheme. wt: wild-ty...
<p>(A) microarray scanning of the Cy3 fluorescence signal corresponding to the wild-type allele. Spo...
<p>(A) Cy3 fluorescence signal corresponding to the wild-type allele. Spots in column 1,2,3,4 repres...
Formalin-fixed, paraffin-embedded (FFPE) tissues used for pathological diagnosis are valuable for st...
A) Picture showing the setup utilized to realize the calibration curves for the KRAS codon 12–13 mut...
A) Microarray scanning of the Cy3 fluorescence signal of four different plasma samples. Only the par...
OBJECTIVES: Molecular genetic analysis of formalin-fixed, paraffin-embedded (FFPE) tissues is of gre...
Next generation sequencing is increasingly used as a diagnostic tool in the clinical setting. This i...
<p>Bar-histograms representing fluorescence intensities from the in-house barcode-chip for genotypin...
OBJECTIVES: Molecular genetic analysis of formalin-fixed, paraffin-embedded (FFPE) tissues is of gre...
identifying actionable mutations in tumors. Accu-rate detection of mutations is often problematic in...
Next generation sequencing is increasingly used as a diagnostic tool in the clinical setting. This i...
<p>Sequencing chromatographs are shown for the products from the real-time traditional PCR (top row)...
identifying actionable mutations in tumors. Accurate detection of mutations is often problematic in ...
Abstract Advanced cancer genomics technologies are now being employed in clinical sequencing, where ...
<p>(A) Cy5 fluorescence signal corresponding to the mutated allele. (B) spotting scheme. wt: wild-ty...
<p>(A) microarray scanning of the Cy3 fluorescence signal corresponding to the wild-type allele. Spo...
<p>(A) Cy3 fluorescence signal corresponding to the wild-type allele. Spots in column 1,2,3,4 repres...
Formalin-fixed, paraffin-embedded (FFPE) tissues used for pathological diagnosis are valuable for st...
A) Picture showing the setup utilized to realize the calibration curves for the KRAS codon 12–13 mut...
A) Microarray scanning of the Cy3 fluorescence signal of four different plasma samples. Only the par...
OBJECTIVES: Molecular genetic analysis of formalin-fixed, paraffin-embedded (FFPE) tissues is of gre...
Next generation sequencing is increasingly used as a diagnostic tool in the clinical setting. This i...
<p>Bar-histograms representing fluorescence intensities from the in-house barcode-chip for genotypin...
OBJECTIVES: Molecular genetic analysis of formalin-fixed, paraffin-embedded (FFPE) tissues is of gre...
identifying actionable mutations in tumors. Accu-rate detection of mutations is often problematic in...
Next generation sequencing is increasingly used as a diagnostic tool in the clinical setting. This i...
<p>Sequencing chromatographs are shown for the products from the real-time traditional PCR (top row)...
identifying actionable mutations in tumors. Accurate detection of mutations is often problematic in ...
Abstract Advanced cancer genomics technologies are now being employed in clinical sequencing, where ...